DK2525782T3 - Formuleringer af nanobærere og fremgangsmåder til fremstilling deraf - Google Patents

Formuleringer af nanobærere og fremgangsmåder til fremstilling deraf Download PDF

Info

Publication number
DK2525782T3
DK2525782T3 DK11732743.7T DK11732743T DK2525782T3 DK 2525782 T3 DK2525782 T3 DK 2525782T3 DK 11732743 T DK11732743 T DK 11732743T DK 2525782 T3 DK2525782 T3 DK 2525782T3
Authority
DK
Denmark
Prior art keywords
nanotubes
formulations
making
methods
Prior art date
Application number
DK11732743.7T
Other languages
English (en)
Inventor
Manish Doshi
Divyesh Sherdiwala
Prakash Sojitra
Original Assignee
Concept Medical Res Private Limited
Envision Scient Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concept Medical Res Private Limited, Envision Scient Private Limited filed Critical Concept Medical Res Private Limited
Application granted granted Critical
Publication of DK2525782T3 publication Critical patent/DK2525782T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
    • A61L2300/624—Nanocapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
    • A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK11732743.7T 2010-01-18 2011-01-06 Formuleringer af nanobærere og fremgangsmåder til fremstilling deraf DK2525782T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN133MU2010 2010-01-18
PCT/IN2011/000006 WO2011086574A2 (en) 2010-01-18 2011-01-06 Formulations of nano-carriers and methods of preparing the same

Publications (1)

Publication Number Publication Date
DK2525782T3 true DK2525782T3 (da) 2019-06-11

Family

ID=44304741

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11732743.7T DK2525782T3 (da) 2010-01-18 2011-01-06 Formuleringer af nanobærere og fremgangsmåder til fremstilling deraf

Country Status (9)

Country Link
US (1) US20120321670A1 (da)
EP (1) EP2525782B1 (da)
CA (1) CA2786671A1 (da)
DK (1) DK2525782T3 (da)
ES (1) ES2726952T3 (da)
PL (1) PL2525782T3 (da)
PT (1) PT2525782T (da)
TR (1) TR201906372T4 (da)
WO (1) WO2011086574A2 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3002989C (en) 2013-10-14 2021-03-16 Nanosphere Health Sciences, Llc Nanoparticle compositions and methods as carriers of nutraceutical factors across cell membranes and biological barriers
WO2016044482A1 (en) * 2014-09-17 2016-03-24 Vivacelle Bio, Inc. Stable micelle and/or liposome compositions and uses thereof
CA3050535C (en) 2014-12-15 2021-11-09 Richard Clark Kaufman Methods of treating inflammatory disorders and global inflammation with compositions comprising phospholipid nanoparticle encapsulations of anti-inflammatory nutraceuticals
CN104586817A (zh) * 2015-02-11 2015-05-06 苏州大学 一种多西他赛固体脂质纳米粒冻干制剂及其制备方法
AU2015385825A1 (en) 2015-03-10 2017-10-05 Nanosphere Health Sciences, Llc Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
KR20210114409A (ko) 2018-12-11 2021-09-23 디스럽션 랩스 인코퍼레이티드 치료제 전달용 조성물과 이의 이용 및 제조 방법
WO2021194772A1 (en) 2020-03-27 2021-09-30 Boston Scientific Scimed, Inc. Methods for crystallization of drugs
CN111671982A (zh) * 2020-05-08 2020-09-18 北京永益润成科技有限公司 一种药物涂层组合物及其制备方法
CN114886855B (zh) * 2022-05-19 2023-10-03 北京柏欧利诺生物科技有限公司 一种雷公藤红素纳米药物及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208877A1 (en) * 2002-07-01 2004-10-21 Avigdor Levanon Antibodies and uses thereof
AU2003287526A1 (en) * 2002-11-06 2004-06-03 Protein-stabilized liposomal formulations of pharmaceutical agents
US7767219B2 (en) * 2003-01-31 2010-08-03 Boston Scientific Scimed, Inc. Localized drug delivery using drug-loaded nanocapsules
CN1493361A (zh) * 2003-08-29 2004-05-05 上海医药工业研究院 山榆酸甘油酯的脂质纳米粒及其制备方法
JP2007526322A (ja) * 2004-03-02 2007-09-13 マサチューセッツ インスティテュート オブ テクノロジー ナノセル薬物送達系
BRPI0600275A (pt) * 2006-01-03 2007-10-02 Brz Biotecnologia Ltda prótese coronária liberadora de composição medicamentosa para prevenção e tratamento da reestenose e processo de fabricação
US20090110739A1 (en) * 2007-05-15 2009-04-30 University Of North Texas Health Science Center At Forth Worth Targeted cancer chemotherapy using synthetic nanoparticles
DE102007061624A1 (de) * 2007-05-31 2009-06-25 Ernst-Moritz-Arndt-Universität Greifswald Verfahren zur Beschichtung von Oberflächen mit Mikro- und Nanopartikeln mit Hilfe von Plasmaverfahren und dessen Verwendung
CN101167699A (zh) * 2007-11-28 2008-04-30 厦门大学 胰岛素口服缓释制剂及其制备方法
US8343497B2 (en) * 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
RU2605793C2 (ru) * 2009-05-29 2016-12-27 Энвижн Сайентифик Прайвит Лимитед ВОССТАНОВЛЕНИЕ КРОВОТОКА В ЗАБЛОКИРОВАННЫХ АРТЕРИЯХ ЧЕЛОВЕКА ПУТЕМ ПЕРЕНОСА НАНОИНКАПСУЛИРОВАННОГО ЛЕКАРСТВЕННОГО СРЕДСТВА ПОСРЕДСТВОМ МЕДИЦИНСКИХ УСТРОЙСТВ, РАЗРАБОТАННЫХ ДЛЯ ЭТОГО, И ВЫСВОБОЖДЕНИЯ НАНОИНКАПСУЛИРОВАННОГО ЛЕКАРСТВЕННОГО СРЕДСТВА В АРТЕРИИ ЧЕЛОВЕКА ПРИ УРОВНЕ pH ОРГАНИЗМА
CN102458555B (zh) * 2009-06-02 2015-12-16 概念医疗股份有限公司 用含治疗剂的包埋纳米颗粒包衣的非植入医疗设备

Also Published As

Publication number Publication date
WO2011086574A2 (en) 2011-07-21
TR201906372T4 (tr) 2019-05-21
PT2525782T (pt) 2019-06-06
ES2726952T3 (es) 2019-10-10
EP2525782B1 (en) 2019-03-13
PL2525782T3 (pl) 2019-09-30
US20120321670A1 (en) 2012-12-20
EP2525782A2 (en) 2012-11-28
CA2786671A1 (en) 2011-07-21
WO2011086574A3 (en) 2011-11-10
EP2525782A4 (en) 2014-05-28

Similar Documents

Publication Publication Date Title
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
DK2648742T3 (da) Formuleringer indeholdende saponiner og anvendelser deraf
DK2872153T3 (da) Accellulære pro-tolerogene sammensætninger og fremgangsmåde til fremstilling heraf
DK3795573T3 (da) Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf
DK2648809T3 (da) Naturlige formuleringer
DK2525782T3 (da) Formuleringer af nanobærere og fremgangsmåder til fremstilling deraf
DK2739293T3 (da) Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus
DK3202460T3 (da) Arylmethoxy-isoindolinderivater og sammensætninger omfattende og fremgangsmåder til anvendelser af samme
DK2694091T3 (da) Fremgangsmåde til fremstilling af kompakte tale-nukleaser og anvendelse heraf
DK2593463T3 (da) Formuleringer af rifaximin og anvendelser deraf
DK3213738T3 (da) Sammensætninger og fremgangsmåder til målrettet termomodulering
DK2691443T3 (da) Konjugerede lipomerer og anvendelser af disse
DK3252057T3 (da) Multicykliske forbindelser og fremgangsmåder til anvendelse deraf
DK3339323T3 (da) Anti-n3pglu-amyloid-beta-peptid-antistoffer og anvendelser deraf
DK3662932T3 (da) Anti-cgrp-sammensætninger og anvendelse deraf
DK2675827T3 (da) Hidtil ukendte modulatorer og fremgangsmåder til anvendelse
DK2602089T3 (da) Resinform til nanotryk og fremgangsmåde til fremstilling deraf
DK2567240T4 (da) Lipidomiske biomarkører til aterosklerose og kardiovaskulær sygdom
DK2498756T3 (da) Tabletformuleringer af neratinibmaleat
DK2663864T3 (da) Fremgangsmåde til at vurdere immundiversitet og anvendelse af denne
DK2892912T3 (da) C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf
DK2600715T3 (da) Flydende ST-246-formuleringer og fremgangsmåder
DK2533761T3 (da) Fremgangsmåder og sammensætninger til fremstilling af aerosoler
DK2647068T3 (da) Batterielektrode og metode til fremstilling af samme
DK3831406T3 (da) Stabile formuleringer af Neisseria-Meningitidis-RLP2086-antigener